[1] Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.?Circ Res. 2013;112(11):1479-1490. DOI:
10.1161/CIRCRESAHA.111.300367[2] Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome.?N Engl J Med. 2014;371(23):2200-2206. DOI:
10.1056/NEJMoa1400284[3] Post N, Yu R, Greenlee S, et al. Metabolism and Disposition of Volanesorsen, a 2'-O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos. 2019;47(10):1164-1173. DOI:
10.1124/dmd.119.087395[4] Lightbourne M, et al. Volanesorsen, an Antisense Oligonucleotide to Apolipoprotein-CIII, Decreases Triglycerides and Increases Lipoprotein Lipase Activity in Partial Lipodystrophy[J]. Journal of the Endocrine Society, 2021, 5(Supplement_1): A305-A305. DOI:
10.1016/j.jacl.2022.06.011[5] Paik J, et al. Volanesorsen: first global approval[J]. Drugs, 2019, 79(12): 1349-1354. DOI:
10.1007/s40265-019-01168-z